A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson's Disease

Download This Paper Open PDF in Browser Add Paper to My Library Share: Permalink Using these links will ensure access to this page indefinitely Copy URL Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com. A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson's Disease 32 Pages Posted: 12 Sep 2022 See all articles by Elliot HoggElliot HoggCedars Sinai Medical Center - Department of NeurologyTina WuCedars Sinai Medical Center - Department of NeurologyCatherine BreseeCedars Sinai Medical Center - Biostatistics CoreJeffrey WertheimerCedars Sinai Medical Center - Department of Physical Medicine and RehabilitationCamille MalattCedars Sinai Medical Center - Department of NeurologyEcho TanCedars Sinai Medical Center - Department of NeurologyHayley PomeroyCedars Sinai Medical Center - Department of NeurologyMiriam NunoUniversity of California, Davis - Department of Public Health SciencesRichard WyseCure Parkinson'sMichele TagliatiCedars Sinai Medical Center - Department of Neurology More... Abstract Background: Metabolic disorders such as insulin resistance and diabetes are associated with Parkinson’s disease (PD). Therefore, the identification and repurposing of drugs already used to treat insulin resistance, like glucagon-like peptide-1 (GLP-1) agonists, is a promising treatment strategy for PD. Liraglutide is a powerful GLP-1 agonist, used in diabetes and obesity treatment.Methods: In a single-center, randomized, double-blind, placebo-controlled trial, PD patients self-administered liraglutide injections once-daily (1.2 or 1.8 mg, as tolerated) or placebo in a 2:1 study design for 52 weeks after titration. Primary outcomes included adjusted difference in the OFF-state Movement Disorders Society Unified PD Rating Scale (MDS-UPDRS) part III, non-motor symptom scale (NMSS) and Mattis Dementia Rating Scale (MDRS-2) at week 54. Secondary outcomes included global MDS-UPDRS scores and subscores, quality of life scores (Parkinson Disease Questionnaire, PDQ-39) and other neuropsychological tests. Efficacy analyses were based on an intention-to-treat and per-protocol design for patients completing post-randomization follow-up assessments.Findings: Sixty-three subjects were enrolled and randomized to liraglutide (n=42) or placebo (n=21). There were 12 early withdrawals (9 liraglutide, 3 placebo), 4 of whom completed week 28 endpoint assessments. At 54 weeks, NMSS scores had improved by 6.6 points in the liraglutide group and worsened by 6.5 points in the placebo group, a 13.1 point adjusted mean difference (p<0.05). MDS-UPDRS part III and MDRS-2 score changes did not significantly differ between liraglutide and placebo. Secondary outcome analyses revealed a significant improvement of MDS-UPDRS part II (p=0.001), PDQ-39 (p<0.001), and Parkinson's Anxiety Scale Avoidance Behavior scores (p<0.05) in the treatment group. MDRS-2 sub-scores did not further differentiate study groups, while Delis-Kaplan Executive Function System letter fluency scores favored placebo group (p<0.05). Injection site reactions and gastrointestinal symptoms were common adverse events (AEs). Eleven serious AEs (9 liraglutide, 2 placebo) were reported, none related to the trial intervention.Interpretation: Treatment with liraglutide is safe and improves critical features of PD, including non-motor symptoms, overall mobility, activities of daily living, and quality of life. These results validate similar outcomes reported with other GLP-1 agonists and offer new strategies to comprehensively treat a larger variety of PD symptoms.Trial Registration: Our trial is registered with ClinicalTrials.gov, NCT02953665Funding: Cure Parkinson’sDeclaration of Interest: MT has received honoraria from Abbott, Acorda, Allergan, Boston Scientific and Medtronic. ET reports consulting fees from Abbvie. JW privately owns stocks in Novo Nordisk, the study drug manufacturer. All other authors declare no competing interests.Ethical Approval: Cedars-Sinai Institutional Review Board (CSMC IRB) approved this study, IRB approval number, (Pro#0044598) dated 8/8/2016. Keywords: Parkinson's disease, liraglutide, glucagon-like peptide-1, clinical trial Suggested Citation: Suggested Citation Hogg, Elliot and Wu, Tina and Bresee, Catherine and Wertheimer, Jeffrey and Malatt, Camille and Tan, Echo and Pomeroy, Hayley and Nuno, Miriam and Wyse, Richard and Tagliati, Michele, A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson's Disease. Available at SSRN: https://ssrn.com/abstract=4212371 Elliot Hogg Cedars Sinai Medical Center - Department of Neurology ( email ) Tina Wu Cedars Sinai Medical Center - Department of Neurology ( email ) Catherine Bresee Cedars Sinai Medical Center - Biostatistics Core ( email ) Jeffrey Wertheimer Cedars Sinai Medical Center - Department of Physical Medicine and Rehabilitation ( email ) Camille Malatt Cedars Sinai Medical Center - Department of Neurology ( email ) Echo Tan Cedars Sinai Medical Center - Department of Neurology ( email ) Hayley Pomeroy Cedars Sinai Medical Center - Department of Neurology ( email ) Miriam Nuno University of California, Davis - Department of Public Health Sciences ( email ) Richard Wyse Cure Parkinson's ( email ) Michele Tagliati (Contact Author) Cedars Sinai Medical Center - Department of Neurology ( email ) Download This Paper Open PDF in Browser Please enable JavaScript to view the comments powered by Disqus. Click here to go to TheLancet.com Go to TheLancet.com Paper statistics Abstract Views 158 Downloads 31 PlumX Metrics Preprints with The Lancet Specialties All Journals (12588) Allergy & Immunology (986) Anaesthesia & Analgesia (36) Cardiology & Vascular Medicine (869) Child & Adoloscence Health (1017) Critical Care (514) Dermatology (86) Digital Health (576) Endocrinology (749) Gastroenterology (740) Genetics & Genomics (2055) Geriatrics (148) Global Health (877) Haematology (547) Infectious Diseases (4713) Nephrology (283) Neurology (1168) Nutrition (438) Obstetrics & Gynaecology (625) Oncology (2765) Ophthalmology (184) Otolaryngology (95) Planetary Health (154) Primary Care (810) Psychiatry (906) Public Health (2902) Radiology & Medical Imaging (427) Respiratory Medicine (532) Rheumatology & Orthopaedics (429) Surgery (338) Urology (81) Related eJournals Preprints with The Lancet Follow Preprints with The Lancet Subscribe to this free journal for more curated articles on this topic FOLLOWERS 242 PAPERS 12,588 Neurology eJournal Follow Neurology eJournal Subscribe to this free journal for more curated articles on this topic FOLLOWERS 78 PAPERS 2,571 Primary Care eJournal Follow Primary Care eJournal Subscribe to this fee journal for more curated articles on this topic FOLLOWERS 49 PAPERS 785 Feedback Feedback to SSRN Feedback (required) Email (required) Submit If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday. SSRN Quick Links SSRN Solutions Research Paper Series Conference Papers Partners in Publishing Jobs & Announcements Newsletter Sign Up SSRN Rankings Top Papers Top Authors Top Organizations About SSRN SSRN Objectives Network Directors Presidential Letter Announcements Contact us FAQs Copyright Terms and Conditions Privacy Policy We use cookies to help provide and enhance our service and tailor content. To learn more, visit Cookie Settings. This page was processed by aws-apollo-4dc in 0.375 seconds